Attention Deficit Hyperactivity Disorder Pipeline, Clinical Trials Assessment, and FDA Approvals 2023 (Updated)

Posted on
by

Attention Deficit Hyperactivity Disorder Pipeline, Clinical Trials Assessment, and FDA Approvals 2023 (Updated)

DelveInsight’s, “Attention Deficit Hyperactivity Disorder Pipeline Insight 2023” report provides comprehensive insights about 20+ companies and 22+ pipeline drugs in the Attention Deficit Hyperactivity Disorder pipeline landscape. It covers the Attention Deficit Hyperactivity Disorder pipeline drug profiles, including Attention Deficit Hyperactivity Disorder clinical trials and nonclinical stage products. It also covers the Attention Deficit Hyperactivity Disorder pipeline therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

 

Key Takeaways from the Attention Deficit Hyperactivity Disorder Pipeline Report

  • DelveInsight’s Attention Deficit Hyperactivity Disorder pipeline report depicts a robust space with 20+ active players working to develop 22+ pipeline therapies for Attention Deficit Hyperactivity Disorder treatment.
  • The leading companies working in the Attention Deficit Hyperactivity Disorder Market include Cingulate Therapeutics, Otsuka Pharmaceutical, BioLite, Mind Medicine, Tris Pharma, RespireRx Pharmaceuticals, KemPharm, Arbor Pharmaceuticals, Ensysce Biosciences, 3Z Pharmaceuticals, and others.
  • Promising Attention Deficit Hyperactivity Disorder Pipeline Therapies in the various stages of development include Guanfacine hydrochloride (TAK-503), Atomoxetine hydrochloride, NFC-1, NRP104, Dasotraline, and others.
  • June 2023: Shire announced a study of phase 4 clinical trials for Guanfacine hydrochloride (TAK-503) and Atomoxetine hydrochloride. The main aim of this study is learn more about long-term treatment of children and teenagers with ADHD for whom earlier stimulant therapy did not work.
  • July 2023: Otsuka Pharmaceutical Development & Commercialization Inc. announced a study of phase 1 clinical trials for Centanafadine. This is a phase 1b, multicenter, open-label, multiple-dose trial in pediatric subjects (4 – 12 years of age, inclusive) with a confirmed diagnosis of ADHD.

 

Request a sample and discover the recent advances in Attention Deficit Hyperactivity Disorder Treatment Drugs @ Attention Deficit Hyperactivity Disorder Pipeline Report

 

In the Attention Deficit Hyperactivity Disorder pipeline report, detailed description of the drug is given which includes mechanism of action of the drug, Attention Deficit Hyperactivity Disorder clinical trials studies, Attention Deficit Hyperactivity Disorder NDA approvals (if any), and product development activities comprising the technology, Attention Deficit Hyperactivity Disorder collaborations, licensing, mergers and acquisition, funding, designations and other product related details.

 

Attention Deficit Hyperactivity Disorder Overview

Attention Deficit-Hyperactivity Disorder (ADHD) is a psychiatric condition that has long been recognized as affecting children’s ability to function. Individuals suffering from this disorder show patterns of developmentally inappropriate levels of inattentiveness, hyperactivity, or impulsivity.

 

Find out more about Attention Deficit Hyperactivity Disorder Therapeutics Assessment @ Attention Deficit Hyperactivity Disorder Preclinical and Discovery Stage Products

 

Attention Deficit Hyperactivity Disorder Emerging Drugs Profile

  • CTx-1301: Cingulate Therapeutics
  • Centanafadine: Otsuka Pharmaceutical
  • PDC-1421: BioLite, Inc.

 

Attention Deficit Hyperactivity Disorder Pipeline Therapeutics Assessment

There are approx. 20+ key companies which are developing the Attention Deficit Hyperactivity Disorder therapies. The Attention Deficit Hyperactivity Disorder companies which have their Attention Deficit Hyperactivity Disorder drug candidates in the most advanced stage, i.e. phase III include, Cingulate Therapeutics.

 

Learn more about the emerging Attention Deficit Hyperactivity Disorder Pipeline Therapies @ Attention Deficit Hyperactivity Disorder Clinical Trials Assessment

 

Scope of the Attention Deficit Hyperactivity Disorder Pipeline Report

  • Coverage- Global
  • Attention Deficit Hyperactivity Disorder Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
  • Attention Deficit Hyperactivity Disorder Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III
  • Attention Deficit Hyperactivity Disorder Companies- Cingulate Therapeutics, Otsuka Pharmaceutical, BioLite, Mind Medicine, Tris Pharma, RespireRx Pharmaceuticals, KemPharm, Arbor Pharmaceuticals, Ensysce Biosciences, 3Z Pharmaceuticals, and others.
  • Attention Deficit Hyperactivity Disorder Pipeline Therapies- Guanfacine hydrochloride (TAK-503), Atomoxetine hydrochloride, NFC-1, NRP104, Dasotraline, and others.

 

Dive deep into rich insights for new drugs for Attention Deficit Hyperactivity Disorder treatment, Visit @ Attention Deficit Hyperactivity Disorder Market Drivers and Barriers, and Future Perspective

 

Table of Content

  1. Introduction
  2. Attention Deficit Hyperactivity Disorder Executive Summary
  3. Attention Deficit Hyperactivity Disorder: Overview
  4. Attention Deficit Hyperactivity Disorder Pipeline Therapeutics
  5. Attention Deficit Hyperactivity Disorder Therapeutic Assessment
  6. Attention Deficit Hyperactivity Disorder– DelveInsight’s Analytical Perspective
  7. Late Stage Products (Phase III)
  8. CTx-1301: Cingulate Therapeutics
  9. Drug profiles in the detailed report…..
  10. Mid Stage Products (Phase II)
  11. MM-120: Mind Medicine
  12. Drug profiles in the detailed report…..
  13. Preclinical and Discovery Stage Products
  14. Drug name: Company name
  15. Drug profiles in the detailed report…..
  16. Inactive Products
  17. Attention Deficit Hyperactivity Disorder Key Companies
  18. Attention Deficit Hyperactivity Disorder Key Products
  19. Attention Deficit Hyperactivity Disorder- Unmet Needs
  20. Attention Deficit Hyperactivity Disorder- Market Drivers and Barriers
  21. Attention Deficit Hyperactivity Disorder- Future Perspectives and Conclusion
  22. Attention Deficit Hyperactivity Disorder Analyst Views
  23. Attention Deficit Hyperactivity Disorder Key Companies
  24. Appendix

 

For further information on the Attention Deficit Hyperactivity Disorder pipeline therapeutics, reach out to Attention Deficit Hyperactivity Disorder Unmet Needs and Analyst Views

 

About Us

DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: 9193216187
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/consulting/ci-tracking